For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 30,496 | |||
| General and administrative | 17,770 | |||
| Total operating expenses | 48,266 | |||
| Loss from operations | -48,266 | |||
| Grant income | 89 | |||
| Interest income | 3,915 | |||
| Interest expense | 2,119 | |||
| Change in fair value of warrant liabilities | -8,199 | |||
| Total other income (expense), net | 10,084 | |||
| Net loss and comprehensive loss | -38,182 | |||
| Basic EPS | -0.72 | |||
| Diluted EPS | -0.72 | |||
| Basic Average Shares | 52,958,644 | |||
| Diluted Average Shares | 52,958,644 | |||
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)